Cargando…
Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies
Rapid advances in immunotherapy have identified adoptive cell transfer as one of the most promising approaches for the treatment of cancers. Large numbers of cancer reactive T lymphocytes can be generated ex vivo from patient blood by genetic modification to express chimeric antigen receptors (CAR)...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154965/ https://www.ncbi.nlm.nih.gov/pubmed/34035114 http://dx.doi.org/10.1136/jitc-2021-002555 |
_version_ | 1783699108869963776 |
---|---|
author | Tantalo, Daniela GM Oliver, Amanda J von Scheidt, Bianca Harrison, Aaron J Mueller, Scott N Kershaw, Michael H Slaney, Clare Y |
author_facet | Tantalo, Daniela GM Oliver, Amanda J von Scheidt, Bianca Harrison, Aaron J Mueller, Scott N Kershaw, Michael H Slaney, Clare Y |
author_sort | Tantalo, Daniela GM |
collection | PubMed |
description | Rapid advances in immunotherapy have identified adoptive cell transfer as one of the most promising approaches for the treatment of cancers. Large numbers of cancer reactive T lymphocytes can be generated ex vivo from patient blood by genetic modification to express chimeric antigen receptors (CAR) specific for tumor-associated antigens. CAR T cells can respond strongly against cancer cells, and adoptive transferred CAR T cells can induce dramatic responses against certain types of cancers. The ability of T cells to respond against disease depends on their ability to localize to sites, persist and exert functions, often in an immunosuppressive microenvironment, and these abilities are reflected in their phenotypes. There is currently intense interest in generating CAR T cells possessing the ideal phenotypes to confer optimal antitumor activity. In this article, we review T cell phenotypes for trafficking, persistence and function, and discuss how culture conditions and genetic makeups can be manipulated to achieve the ideal phenotypes for antitumor activities. |
format | Online Article Text |
id | pubmed-8154965 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-81549652021-06-10 Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies Tantalo, Daniela GM Oliver, Amanda J von Scheidt, Bianca Harrison, Aaron J Mueller, Scott N Kershaw, Michael H Slaney, Clare Y J Immunother Cancer Review Rapid advances in immunotherapy have identified adoptive cell transfer as one of the most promising approaches for the treatment of cancers. Large numbers of cancer reactive T lymphocytes can be generated ex vivo from patient blood by genetic modification to express chimeric antigen receptors (CAR) specific for tumor-associated antigens. CAR T cells can respond strongly against cancer cells, and adoptive transferred CAR T cells can induce dramatic responses against certain types of cancers. The ability of T cells to respond against disease depends on their ability to localize to sites, persist and exert functions, often in an immunosuppressive microenvironment, and these abilities are reflected in their phenotypes. There is currently intense interest in generating CAR T cells possessing the ideal phenotypes to confer optimal antitumor activity. In this article, we review T cell phenotypes for trafficking, persistence and function, and discuss how culture conditions and genetic makeups can be manipulated to achieve the ideal phenotypes for antitumor activities. BMJ Publishing Group 2021-05-25 /pmc/articles/PMC8154965/ /pubmed/34035114 http://dx.doi.org/10.1136/jitc-2021-002555 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Tantalo, Daniela GM Oliver, Amanda J von Scheidt, Bianca Harrison, Aaron J Mueller, Scott N Kershaw, Michael H Slaney, Clare Y Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies |
title | Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies |
title_full | Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies |
title_fullStr | Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies |
title_full_unstemmed | Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies |
title_short | Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies |
title_sort | understanding t cell phenotype for the design of effective chimeric antigen receptor t cell therapies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154965/ https://www.ncbi.nlm.nih.gov/pubmed/34035114 http://dx.doi.org/10.1136/jitc-2021-002555 |
work_keys_str_mv | AT tantalodanielagm understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies AT oliveramandaj understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies AT vonscheidtbianca understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies AT harrisonaaronj understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies AT muellerscottn understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies AT kershawmichaelh understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies AT slaneyclarey understandingtcellphenotypeforthedesignofeffectivechimericantigenreceptortcelltherapies |